William Blair Gives a Buy Rating to Spark Therapeutics

William Blair analyst Raju Prasad assigned a Buy rating to Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares closed yesterday at $74.83.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 30.2% and a 76.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and PTC Therapeutics.

Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $83.70, representing an 11.9% upside.

In a report issued on May 8, Mizuho Securities also maintained a Buy rating on the stock with a $91 price target.

See today’s analyst top recommended stocks >>

Based on Spark Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $46.37 million. In comparison, last year the company had a GAAP net loss of $52.29 million.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.